Indegene Inc | July 05, 2022
Indegene, a technology-led healthcare solutions provider, announced a partnership with Amwell®, a digital care delivery leader. This collaboration will facilitate life sciences organizations to connect patients to better quality care and drive better health outcomes.
Digital patient engagement has disrupted the healthcare landscape. Patients are increasingly becoming more knowledgeable and involved in their health journeys. They want personalized support solutions that are available on the go. The technology partnership between Indegene and Amwell will enable life sciences organizations to transform their patient support capabilities and engage with patients across digital, virtual, and physical mediums. It will allow Indegene to include Amwell’s digital care platform Converge™ into its end-to-end patient support framework and enable life sciences organizations to offer a personalized care model.
"Patient needs are rapidly evolving, and life sciences organizations often struggle to provide customized solutions that cater to them. By partnering with Amwell, we hope to equip life sciences organizations with customized patient engagement solutions that boost access to cutting-edge treatments and improve health outcomes,"
Nitin Raizada, Vice President, Enterprise Commercial at Indegene
This partnership will facilitate Indegene to enable life sciences organizations to drive virtual care automation and patient companionship to advance longitudinal care, behavioral health, and other specialty and chronic care segments. It will help patients access treatments they need and receive continued support to remain adherent through their health journeys.
“As the future of care becomes increasingly hybrid, we are excited to partner with Indegene to further expand access to our Amwell Converge Platform and help accelerate their path to market with access to our installed base of payer and provider customers,” said Rene Barron, VP Channel Management, Amwell. “Together with Indegene, we aim to ensure that all life sciences organizations can more easily connect patients to quality care to improve clinical and financial outcomes, as well as delight patients with personalized care experiences.”
Indegene is a technology-led healthcare solutions provider. It combines deep industry expertise with fit-for-purpose technology in an agile and scalable operating model. Many of the leading, global healthcare organizations rely on Indegene to deliver effective and efficient clinical, medical and commercial outcomes every day. From strategy to execution, Indegene enables healthcare organizations to be future ready.
Amwell is a leading digital care delivery platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers the digital health solutions for over 2,000 hospitals and 55 health plan partners with over 36,000 employers, covering over 80 million lives.
American Well, Amwell, SilverCloud, Conversa, Converge and Carepoint are registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.
FUTURE OF HEALTHCARE
Spinafx medical inc | June 13, 2022
Minimally invasive image-guided therapy company, SpinaFX Medical Inc. announced it will exhibit at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting inBoston, MA,June 11-16, at booth 414. Dr. Alexis Kelekis, medical advisor to SpinaFX, will present the results of a research study on which he was the lead author, recently published inThe Spine Journal, on the effectiveness of intradiscal oxygen-ozone treatment compared to microdiscectomy for contained lumbar disc herniation with radiculopathy. This study has been recognized by SIR as one of the 2022Abstracts of the Year.
"We are excited to meet with some of the world's leading interventional radiologists to discuss innovations in minimally invasive, image-guided care and share our recent progress and momentum at SpinaFX. We look forward to Dr. Kelekis' presentation and celebrate the study's findings, which have the potential to benefit both patients and providers by addressing a significant gap in the continuum of care for the millions suffering from back pain."
Jeff Cambra, SpinaFX CEO
"I am thrilled that Dr. Kelekis will share the findings of our skilled research team at SIR's Annual Scientific Meeting," said Dr.Kieran Murphy, SpinaFX Chief Medical Officer and co-author of the recognized study. "The technology used in this randomized control trial holds great promise for patients struggling with contained herniated lumbar disc pain and it is an honor to have this research recognized by such a prestigious and well-respected organization."
Dr. Alexis Kelekis willpresentthe results of his study onWednesday, June 15, at10:40 a.m.during Closing Plenary.
As an exhibitor during the meeting onJune 11-16, SpinaFX will offer attendees the opportunity to discuss the study results and their implications with Drs. Kelekis and Murphy, learn more about SpinaFX and its goal to help develop minimally invasive, image-guided treatment options, and provide input on developing technology with the potential to redefine the treatment of contained herniated discs. Visit SIR'swebsiteto learn more about the Annual Scientific Meeting.
Headquartered inOntario, Canada, SpinaFX is a treatment solution and technology company bringing innovative, minimally invasive image-guided treatments to patients with back pain due to contained herniated discs.
FUTURE OF HEALTHCARE
Virta Health | June 07, 2022
Virta Health, the leader in type 2 diabetes reversal, revealed preliminary five-year results from its landmark clinical trial at the American Diabetes Association 82nd Scientific Sessions. Presenting four unique abstracts, Virta highlighted myriad, lasting health improvements for people with type 2 diabetes and prediabetes, including blood sugar control, clinically-significant weight loss, reduced inflammation, and improvements in other markers of cardiometabolic health.
These transformative health outcomes coincided with medication reduction or elimination for many trial patients, including Jane Ann Dimitt.
For over two decades, Jane Ann was prescribed increasing levels of medications as her blood sugar and weight continued to climb. By the time she joined Virta in 2015, her A1c had reached 11.4%; the next step was insulin. Through Virta’s treatment, Jane Ann lowered her blood sugar to 5.5% (below even the prediabetes threshold) and lost over 50 pounds, while drastically reducing her reliance on medications. She also saw improved mobility, decreased inflammation and neuropathy, and now has the energy to play with her grandchildren—all without needing the insulin doctors said was imminent.
The outcomes of Jane Ann and Virta’s other trial patients contradict the belief that progression of diabetes—and a lifetime of increasing medications—is inevitable. One-fifth of Virta patients completing five years of treatment saw full remission. One-third of patients achieved A1c below 6.5% without any diabetes medications, or only requiring Metformin. Notably, inflammatory markers, triglycerides, and HDL cholesterol all improved significantly.
These outcomes, in conjunction with previous research demonstrating improvements in cardiovascular disease risk factors, depression symptoms, sleep, and knee pain, establish the promise of Virta’s approach to impact a wide range of conditions amid America’s metabolic disease epidemic. In the U.S., costs are rising as patient outcomes continue to worsen, including surges in amputations, hyperglycemic events, and diabetes-related deaths during the COVID-19 pandemic.
Meanwhile, getting patients to stick with an intervention remains a significant challenge in diabetes therapy. Rates of medication adherence—that is, whether patients take their medications as prescribed—fall as low as 34% over the first three years for those starting insulin. For the National Diabetes Prevention Program, considered the gold standard in lifestyle interventions, only 13% of patients were retained at one year.
In contrast, in Virta’s trial nearly 50% of participants with type 2 diabetes were retained at five years. Of those who continued past year two, 72% remained for an additional three years to year five. For Kim Shepherd, who lost 55 pounds, eliminated 10 different medications, reversed her diabetes, and even saw her GERD (acid reflux) and plantar fasciitis disappear, the reasons to stick with the treatment are clear.
“Diabetes runs in my family, and I know that this disease can rob you of your whole life; it can take your eyes, your feet, and your kidneys. I have 4 kids and 9 grandkids to keep up with. I’ve learned to love hiking and biking. Nothing is worth losing all of that and going back to how I was before.”
Additional key outcomes demonstrating the success of Virta’s approach at five years include
Sustained blood sugar control. Virta patients experienced persistent improvements in blood sugar on average, while requiring significantly fewer medications.
Medication deprescription. Half of patients prescribed insulin at the start of the trial no longer needed it at five years. Across all diabetes drugs, prescriptions were reduced by nearly 50%.
Weight loss. Average weight among Virta participants decreased by 7.6%, exceeding the 5% benchmark for clinically significant weight loss by more than 50%.
Broad improvement in cardiometabolic health. In addition to improvements in triglycerides, HDL cholesterol, and markers of inflammation, patients even showed encouraging signs in reversing the progression of chronic kidney disease.
“Virta’s patients are helping redefine what long-term success can look like in type 2 diabetes care. The patient outcomes set a new standard for real-world applications of diabetes treatment."
Dr. Alan Moses, former Senior Vice President and Global Chief Medical Officer of Novo Nordisk, and Virta advisor
Trial participants with prediabetes also saw meaningful improvements, with progression rates far below what has been demonstrated in other studies. Further, Virta patients sustained 6% weight loss over five years, exceeding the clinically-significant benchmark for diabetes prevention and far surpassing the 2% weight loss observed in the NIH Diabetes Prevention Program lifestyle intervention.
The study is also notable for its longevity. Five-year published results are extremely rare in digital health, where most studies follow populations for no more than a year, and usually significantly less. For many Virta patients, the five-year clinical trial has facilitated a lasting lifestyle change, improving not only traditional markers of health but overall mood, quality of life, and outlook on the future.
Says patient Denise Lamb, who has maintained diabetes reversal alongside a nearly 70 pound weight loss, “My journey has been phenomenal. The Virta program has not only helped me achieve healthy blood glucose, but also attain a far better weight, normal blood pressure, and better understanding of my body. Virta’s lifestyle changed my lifestyle!”
About Virta Health
Virta Health helps people reverse type 2 diabetes and other chronic conditions. Current approaches manage disease progression through increased medication use and infrequent doctor visits. Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts. In clinical studies, 94% of patients reduce or eliminate insulin use, and weight-loss exceeds FDA benchmarks by nearly 150%. Virta works with the largest health plans, employers, and government organizations and puts 100% of its fees at risk based on clinical and financial outcomes.
Viemed Healthcare, Inc. | July 06, 2022
Viemed Healthcare, Inc. a national leader in respiratory care and technology-enabled home medical equipment services, announced a third peer-reviewed and published study demonstrating the benefits of non-invasive ventilation at home The study, titled “Early Initiation of Non-Invasive Ventilation at Home Improves Survival and Reduces Healthcare Costs in COPD Patients with Chronic Hypercapnic Respiratory Failure: A Retrospective Cohort Study” was published in Respiratory Medicine, an internationally renowned scientific journal devoted to respiratory medical research.
“In addition to the significant clinical benefits demonstrated in previously published papers, this study demonstrates that NIVH improves health outcomes while simultaneously driving down overall healthcare costs. The study was also designed to investigate how the timing of NIVH initiation affected the outcomes. The results showed that the clinical and financial benefits of NIVH are greatest when therapy begins immediately following the diagnosis.”
Dr. William Frazier, Viemed’s Chief Medical Officer and co-author of the study
Using the 100% research identifiable fee-for-service Medicare claims from 2016 through 2020, the researchers found that using NIVH to treat chronic obstructive pulmonary disease with chronic hypercapnic respiratory failure is associated with significant reductions in mortality, hospitalizations, and total Medicare costs. In terms of cost-savings, Medicare expenditures for the year following NIVH initiation decreased by $5,484 compared to controls if treatment was begun within seven days of diagnosis. The cost reduction was $3,412 if NIVH was begun within 15 days of diagnosis. For patients whose therapy began more than 15 days after diagnosis, NIVH use was cost neutral and not associated with an increase in Medicare expenditures.
The primary clinical benefit was a reduced mortality in patients treated with NIVH. When a patient began therapy within seven days of diagnosis, the risk of death was reduced by 43%. Those patients who began therapy between eight and 15 days following diagnosis showed a mortality reduction of 31%, and patients who began therapy between 16 and 30 days following diagnosis showed a mortality reduction of 16%.
“NIVH is becoming widely accepted by clinicians as the standard of care for hypercapnic COPD-CRF treatment and this evidence supporting early initiation will help us to communicate the clinical and economic benefits to payors and partners,” said Casey Hoyt, Viemed’s CEO. “By accessing and treating more patients sooner, we can save lives, reduce hospital readmissions, and save money at the same time.”
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology.